You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Niger (OAPI) Drug Patents


✉ Email this page to a colleague

« Back to Dashboard


Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo Brazzaville, Côte d'Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Senegal, Togo

Drug Patents in African Intellectual Property Organization (OAPI) and US Equivalents

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
Patent Number Estimated Expiration Equivalent US Patent US Expiry Date Generic Name US Applicant US Tradename
11304 ⤷  Try for Free 6294540 2018-11-14 abacavir sulfate Viiv Hlthcare ZIAGEN
9193 ⤷  Try for Free 5047407 2010-05-17 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
9470 ⤷  Try for Free 5047407 2010-05-17 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
9913 ⤷  Try for Free 5905082 2016-11-18 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
9559 ⤷  Try for Free 6180639 2018-01-30 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
11304 ⤷  Try for Free 6294540 2018-11-14 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
>Patent Number >Estimated Expiration >Equivalent US Patent >US Expiry Date >Generic Name >US Applicant >US Tradename

Key Insights for Patentability, Enforceability, and the Scope of Claims for Biopharmaceutical Patents in the African Intellectual Property Organization (OAPI) Patent Office

Introduction to OAPI and Its Member States

The African Intellectual Property Organization (OAPI) is a regional intellectual property system that covers 17 French-speaking African countries, including Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Ivory Coast, Mali, Mauritania, Niger, Senegal, and Togo. OAPI was established under the Bangui Agreement on March 2, 1977, to foster cooperation and share common objectives in intellectual property matters[5].

Automatic Protection Across Member States

One of the most distinctive characteristics of OAPI is that a single patent or utility model application automatically grants protection in all member states. This unified protection means that it is not possible to designate specific countries for protection; the application covers all member states uniformly[1][5].

Upcoming Changes to the Bangui Agreement

As of January 1, 2025, significant changes to the Bangui Agreement will come into effect, impacting patent and utility model applications. Here are some key points:

  • Substantive Examination: Patent and utility model applications will be subject to substantive examination. OAPI Patent Examiners have been undergoing training to ensure they are equipped to handle these examinations. For PCT regional phase applications, examiners will rely on the PCT International Search Report and the International Preliminary Examination Report (IPRP)[1].

  • Divisional Applications: It will be possible to file voluntary divisional applications until the notification of grant of a patent or a utility model. Additionally, divisional applications can be filed at any time before grant or in response to a substantive examination Office Action[1].

  • Opposition Proceedings: Patent and utility model opposition will be provided for, with applications being published for opposition purposes. Any interested party can oppose the issuance of a patent or utility model application within three months of the publication[1].

Patentability of Biopharmaceutical Inventions

Pharmaceutical Product Inventions and TRIPS Exclusions

For least developed countries (LDCs) within the OAPI member states, the World Trade Organization's TRIPS agreement has extended the exclusion of pharmaceutical products from patent protection until January 1, 2033. This means that LDCs within OAPI are no longer required to apply the provisions of Annex I regarding patents related to pharmaceutical products[1].

Specificity and Novelty

For biopharmaceutical inventions, the claims must be carefully crafted to ensure they cover all aspects of the invention while avoiding unnecessary breadth. Each claim should be supported by the detailed description and clearly articulate the novel and non-obvious features of the invention. This precision is crucial for strong and enforceable patent protection[3].

Scope of Claims for Biopharmaceutical Patents

Broad and Narrow Claims

When drafting patent claims for biopharmaceutical inventions, it is advisable to start with broad claims that capture the general inventive concept. These broad claims should be followed by narrower, dependent claims that add specific details and limitations. This hierarchical structure ensures comprehensive protection.

For example, a broad claim for a new genetic modification technique might state: “A method for modifying the genome of a plant, comprising introducing a nucleic acid sequence into the plant genome.” Dependent claims could then specify: “wherein the nucleic acid sequence is introduced using CRISPR-Cas9 technology” or “wherein the modified genome enhances drought resistance”[3].

Clarity and Precision

Clarity and precision are paramount in drafting patent claims. Ambiguous or overly broad claims can lead to rejections or challenges, weakening the patent’s enforceability. Each claim must be clearly supported by the detailed description of the invention to ensure that the patent provides strong protection[3].

Enforceability of Biopharmaceutical Patents

Opposition and Post-Grant Proceedings

With the introduction of opposition proceedings, any interested party can oppose the issuance of a patent or utility model application within three months of the publication. This adds a layer of scrutiny and potential challenge to the enforceability of biopharmaceutical patents[1].

Protection Against Infringement

OAPI member states are required to protect peasants against biopiracy and ensure that private contracts cannot override farmers’ rights to seeds and breeding material. However, IP infringement is treated as a civil matter, with the burden of proof lying with the injured party. This means that losses incurred by infringement can be compensated through monetary payments rather than criminal sanctions[4].

Official Fees and Additional Costs

New official fees for patents and utility models will be applicable as of January 1, 2025, although the amended fees have not yet been published. Applicants should be prepared for potential additional costs associated with the new substantive examination process and other changes to the Bangui Agreement[1].

Impact of Regional and International Agreements

OAPI is a member of the Paris Union and the Patent Cooperation Treaty (PCT), which facilitates the filing of international patent applications. This integration ensures that OAPI aligns with international standards and best practices in intellectual property protection, making it easier for biopharmaceutical companies to navigate the regional and global IP landscape[5].

Practical Considerations for Biopharmaceutical Companies

Disclosure and Linkage Systems

While the OAPI system does not have a specific patent linkage system like that in Saudi Arabia, biopharmaceutical companies should still ensure that they disclose any relevant patents when applying for product registration. This helps in preventing the approval of potentially infringing products and protects the exclusivity period of brand-name drugs[2].

Training and Expertise

Given the upcoming changes, including the introduction of substantive examination, it is crucial for biopharmaceutical companies to work with qualified IP attorneys and experts who are familiar with the new procedures and requirements.

Key Takeaways

  • Unified Protection: A single OAPI patent application automatically covers all member states.
  • Substantive Examination: New substantive examination process for patent and utility model applications starting January 1, 2025.
  • Divisional Applications: Voluntary divisional applications can be filed until notification of grant or in response to Office Actions.
  • Opposition Proceedings: Opposition to patent and utility model applications will be allowed within three months of publication.
  • TRIPS Exclusions: LDCs within OAPI are exempt from patent protection for pharmaceutical products until January 1, 2033.
  • Clarity and Precision: Claims must be clear, precise, and supported by detailed descriptions to ensure strong and enforceable protection.
  • Official Fees: New fees will be applicable, but details are yet to be published.

FAQs

Q: What is the scope of protection for an OAPI patent application?

A: An OAPI patent application automatically grants protection in all 17 member states without the possibility of designating specific countries.

Q: What changes are coming to the Bangui Agreement regarding patent and utility model applications?

A: Starting January 1, 2025, applications will be subject to substantive examination, divisional applications can be filed until notification of grant, and opposition proceedings will be allowed.

Q: How do TRIPS exclusions affect pharmaceutical patents in OAPI?

A: Least developed countries within OAPI are exempt from patent protection for pharmaceutical products until January 1, 2033, as per the TRIPS agreement.

Q: What is the importance of clarity and precision in drafting patent claims for biopharmaceutical inventions?

A: Clarity and precision are crucial to avoid rejections or challenges, ensuring that the patent provides strong and enforceable protection.

Q: Are there any new official fees associated with the changes to the Bangui Agreement?

A: Yes, new official fees will be applicable, but the amended fees have not yet been published.

Sources

  1. Spoor.com: Changes to the OAPI system governing Patents and Utility Models
  2. SABA IP: Navigating the Patent Linkage System in Saudi Arabia
  3. PatentPC: How to Draft Patent Claims for Biotech Inventions
  4. Geneva Academy: The Right to Seeds in Africa
  5. Inventa: OAPI Patents

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.